China Jo Jo Drugstores Holdings Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of China Jo Jo Drugstores Holdings Inc (CJJD) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: China Jo Jo Drugstores Holdings Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 132M vs 859,293M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+263.1% annualized vs trailing 12 months), vs decelerating (-6.8%) for its tracked peer group.
- Profitability: Its 8.5% net margin compares with -0.5% for the peer group.
- Peer revenue share: China Jo Jo Drugstores Holdings Inc accounted for 0.1% of combined revenue among its tracked peer group.
- Peer differentiation: Revenue per employee of $2.07M compares with $1.17M for the peer group (1.8x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CJJD Sales vs. its Competitors, Q4 2025
With a net margin of 8.50 %, China Jo Jo Drugstores Holdings Inc achieved higher profitability than its competitors (-0.48 %).
China Jo Jo Drugstores Holdings Inc generated 0.06 % of the combined sales of its peer group.
China Jo Jo Drugstores Holdings Inc vs. its Competitors, Q4 2025
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in China Jo Jo Drugstores Holdings Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across China Jo Jo Drugstores Holdings Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| China Jo Jo Drugstores Holdings Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across China Jo Jo Drugstores Holdings Inc's competitor groups requires a Commercial License.
China Jo Jo Drugstores Holdings Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| China Jo Jo Drugstores Holdings Inc | No | Yes | Yes | No |
| Competitors combined (5) | ||||
| Similar Growth & Profitability (8) | 62.50 % (5 of 8) | 87.50 % (7 of 8) | 62.50 % (5 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CJJD Stock Performance relative to its Competitors
CJJD Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Newell Brands Inc | 282.9% | Outperformed |
| 2 | Cvs Health Corporation | 282.9% | Outperformed |
| 3 | Walgreens Boots Alliance Inc | 282.9% | Outperformed |
| 4 | The Cigna Group | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for China Jo Jo Drugstores Holdings Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
China Jo Jo Drugstores Holdings Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of China Jo Jo Drugstores Holdings Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| China Jo Jo Drugstores Holdings Inc | 110.46 | 132.16 |
| Cvs Health Corporation | 118,867.32 | 415,086.00 |
| The Cigna Group | 79,795.71 | 282,382.00 |
| Walgreens Boots Alliance Inc | 10,361.50 | 154,579.00 |
| Newell Brands Inc | 2,430.63 | 7,246.00 |
| Rite Aid Corp | 35.85 | 23,475.49 |
| SUBTOTAL | 211,601.47 | 882,900.65 |
Sources: China Jo Jo Drugstores Holdings Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on China Jo Jo Drugstores Holdings Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
China Jo Jo Drugstores Holdings Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| China Jo Jo Drugstores Holdings Inc | Offline Wholesale 89.19 % |
| Cvs Health Corporation | Health Services 48.03 % |
| The Cigna Group | Evernorth 85.32 % |
| Walgreens Boots Alliance Inc | United States Retail Pharmacy 78.78 % |
| Newell Brands Inc | Home and Commercial 45.29 % |
| Rite Aid Corp | Retail Pharmacy 73.82 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
China Jo Jo Drugstores Holdings Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| China Jo Jo Drugstores Holdings Inc | 110 | 2,065,058 | -19,538 |
| Cvs Health Corporation | 118,867 | 1,383,620 | 16,283 |
| The Cigna Group | 79,796 | 4,171,078 | 102,555 |
| Walgreens Boots Alliance Inc | 10,362 | 495,446 | -25,365 |
| Newell Brands Inc | 2,431 | 330,868 | -10,091 |
| Rite Aid Corp | 36 | 469,510 | -32,493 |
| PEERS TOTAL | 211,491 | 1,174,519 | 2,752 |
China Jo Jo Drugstores Holdings Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Newell Brands Inc | North America 67.20 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
China Jo Jo Drugstores Holdings Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 13 companies in China Jo Jo Drugstores Holdings Inc's industry classification, broader than the peer set above. Market cap in millions of $.China Jo Jo Drugstores Holdings Inc ranks #0 of 13 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 2,668, indicating a highly concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Mckesson Corporation | 119,777 | 32.40 % |
| 2 | Cvs Health Corporation | 118,867 | 32.16 % |
| 3 | Cencora Inc | 66,119 | 17.89 % |
| 4 | Cardinal Health Inc | 59,958 | 16.22 % |
| 5 | Guardian Pharmacy Services Inc | 1,234 | 5.2% |
| 6 | Herbalife Ltd | 1,234 | 5.2% |
| 7 | 111 Inc | 1,234 | 5.2% |
| 8 | Nu Skin Enterprises Inc | 1,234 | 5.2% |
| 9 | Zerostack Corp | 1,234 | 5.2% |
| 10 | Petmed Express Inc | 1,234 | 5.2% |
| 0 | China Jo Jo Drugstores Holdings Inc | 8 | 0.00 % |
Market cap and industry share for the rest of China Jo Jo Drugstores Holdings Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-03-03.
China Jo Jo Drugstores Holdings Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Pharmacy Services & Retail Drugstore industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (34 companies). See the full Pharmacy Services & Retail Drugstore industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 26.98 % (avg) | -27.0 pp |
| Operating Margin | -1.41 % | industry median | -2.6 pp |
| EBITDA Margin | -1.31 % | -2.89 % (avg) | +1.6 pp |
| Capital Intensity (Capex / Revenue) | 0.00 % | 1.54 % (avg) | -1.5 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
China Jo Jo Drugstores Holdings Inc's Strategic Group Map
Every company in China Jo Jo Drugstores Holdings Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. China Jo Jo Drugstores Holdings Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
China Jo Jo Drugstores Holdings Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Low | Industry HHI of 2,668 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 1.54 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See China Jo Jo Drugstores Holdings Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See China Jo Jo Drugstores Holdings Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
China Jo Jo Drugstores Holdings Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
China Jo Jo Drugstores Holdings Inc falls in the Medium attractiveness / High strength cell: Invest / Grow.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
China Jo Jo Drugstores Holdings Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+263.1% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 19.6 points below the industry aggregate.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-6.8% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
China Jo Jo Drugstores Holdings Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| China Jo Jo Drugstores Holdings Inc | 0.64 | 2.31 | 0.00 |
| Cvs Health Corporation | 0.11 | 0.85 | 0.83 |
| The Cigna Group | 0.12 | 0.82 | 0.76 |
| Walgreens Boots Alliance Inc | 0.03 | 0.63 | 0.88 |
| Newell Brands Inc | 0.08 | 1.09 | 1.97 |
| Rite Aid Corp | 0.03 | 0.97 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
China Jo Jo Drugstores Holdings Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| China Jo Jo Drugstores Holdings Inc | Q1 2025 | +10.2 % | - |
| Cvs Health Corporation | Q2 2026 | +7.3 % | +195.7 % |
| The Cigna Group | Q2 2026 | +6.7 % | +22.4 % |
| Walgreens Boots Alliance Inc | Q2 2025 | +7.2 % | - |
| Newell Brands Inc | Q2 2026 | +3.0 % | +130.4 % |
| Rite Aid Corp | Q3 2023 | -4.3 % | - |
| PEERS TOTAL | +6.7 % | +50.8 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
China Jo Jo Drugstores Holdings Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| China Jo Jo Drugstores Holdings Inc | Q1 2025 | +10.1 % | -99.7 % |
| Cvs Health Corporation | Q2 2026 | +9.0 % | +13.8 % |
| The Cigna Group | Q2 2026 | +6.4 % | - |
| Walgreens Boots Alliance Inc | Q2 2025 | +8.7 % | -10.5 % |
| Newell Brands Inc | Q2 2026 | -5.4 % | -20.3 % |
| Rite Aid Corp | Q3 2023 | -4.1 % | -14.6 % |
China Jo Jo Drugstores Holdings Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| China Jo Jo Drugstores Holdings Inc | - | - | - |
| Cvs Health Corporation | 1.92% | 2.81% | 6.39% |
| The Cigna Group | 4.44% | 6.84% | 16.41% |
| Walgreens Boots Alliance Inc | - | - | - |
| Newell Brands Inc | - | - | - |
| Rite Aid Corp | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
China Jo Jo Drugstores Holdings Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| China Jo Jo Drugstores Holdings Inc | - | 0.84 |
| Cvs Health Corporation | 24.31 | 0.29 |
| The Cigna Group | 12.53 | 0.28 |
| Walgreens Boots Alliance Inc | - | 0.07 |
| Newell Brands Inc | - | 0.34 |
| Rite Aid Corp | - | 0.00 |
| PEERS AVERAGE | 102.37 | 0.24 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.